Revolutionising Early-Stage Breast Cancer Treatment: How the MAF Test® Enhances Precision Care with Biomarker-Driven Insights
Read Article Here:
https://sourcebioscience.com/maf-test-revolutionising-early-stage-breas…
The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.
Join us for an insightful workshop on the art of delegation. This learned skill is the key to unlocking increased productivity as well as personal growth for leaders, senior managers and entrepreneurs. This interactive, informal session is designed to help you master skills that will lead to effective leadership and build trust within your team, empowering others to take ownership. Practical tips will help you prioritise tasks, improve time management, foster collaboration and elevate your leadership potential with smart delegation gaining the headspace you need to move forward.
FDA Regulatory Roadmap - Drop-in Clinic offers UK and European life sciences and medical device companies personalised, 1-on-1 consultations with FDA specialist Mark Swanson. The 20-30 minute sessions will provide tailored guidance on navigating U.S. FDA regulations.
US Market-Entry Masterclass - FDA Regulatory Roadmap is an online masterclass aimed at medical device and life science product companies seeking to expand into the U.S. market. This 90-minute session, organised by GTM Global in association with QRx Partners, will provide crucial guidance on navigating the complex U.S. regulatory landscape, especially FDA requirements.
Job type: 2-year fixed term contract
Location: Oxford
Salary: Competitive salary
Right to work: You must have the right to work in the UK
Being Tested in Combination with MSD’s anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab)
Cambridge, UK – 7 October 2024: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that the first patient has been dosed in its advanced melanoma (MELODY-1) trial. This international trial is due to recruit up to 40 patients at clinical centres in the UK, France, Italy and Spain. Initial data readouts are expected by the end of 2025.
Dr Gordon McInroy appointed as COO, Dr Tobias Ost as SVP Product Development, and Charu Maini as SVP of People
Pioneer Group has announced its successful exit from Alderley Analytical, a leading independent contract research organisation (CRO) specialising in bioanalytical services, following the company’s acquisition by Synexa Life Sciences Ltd, a Dutch-based company backed by major European healthcare investor Gilde Healthcare.